Compugen (NASDAQ:CGEN) Stock Crosses Above 200-Day Moving Average – Here’s Why

Shares of Compugen Ltd. (NASDAQ:CGEN) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.74 and traded as high as $2.12. Compugen shares last traded at $2.07, with a volume of 137,147 shares trading hands.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CGEN shares. HC Wainwright initiated coverage on Compugen in a research report on Wednesday, January 7th. They set a “buy” rating and a $4.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $4.00.

Compugen Stock Performance

The business has a 50 day simple moving average of $1.97 and a 200-day simple moving average of $1.74.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. The company had revenue of $67.33 million for the quarter, compared to the consensus estimate of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%. On average, equities research analysts predict that Compugen Ltd. will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On Compugen

Several hedge funds and other institutional investors have recently bought and sold shares of CGEN. Bank Hapoalim BM acquired a new stake in Compugen in the 4th quarter valued at about $37,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Compugen in the 4th quarter worth approximately $38,000. Franklin Resources Inc. bought a new stake in shares of Compugen in the 2nd quarter worth approximately $56,000. Osaic Holdings Inc. raised its holdings in shares of Compugen by 346.0% in the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 34,045 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Compugen during the fourth quarter valued at approximately $84,000. 12.22% of the stock is currently owned by institutional investors.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.